PPARγ mRNA在胃癌组织中的表达及其与胃癌预后的关系

摘要

目的 检测人胃癌组织中过氧化物酶体增殖物活化受体γ mRNA(PPARγ mRNA)表达,探讨其与胃癌临床病理特征和术后患者预后的关系.方法 采用实时定量PCR技术测定53例胃癌手术患者的癌组织和切缘正常组织中PPARγ mRNA的表达量,对PPARγ mRNA表达量与患者的临床病理参数及预后进行分析.结果 PPARγ mRNA表达量在胃癌组织较切缘正常组织表达高(P＜0.05),PPARγ mRNA的表达量与胃癌的TNM分期有关(P<0.05).PPARγ mRNA高表达者预后较好.结论 胃癌组织中PPARγ mRNA表达与胃癌的TNM分期相关;PPARγ mRNA可作为胃癌患者预后的1个评价指标,并可能成为基因治疗的1个作用靶点.%Objective By quantitative detection of PPAR-γmRNA expression, we investigate the relationship between peroxisome proliferator-activated receptor-γ ( PPARγ ) mRNA and clinicopathological parameters and prognosis in 53 gastric cancer. Methods Expression of PPARγmRNA was detected by real-time PCR in 53 cases of gastric cancer and corresponding non-cancerous tissues. The relationship of PPAR-ymRNA expression with the clinicopathological characteristics and prognosis was analyzed. Results The PPARγmRNA in gastric cancer was significantly higher than that in non-cancemas tissue( P < 0. 05 ). PPARγmRNA expression was significantly associated with TNM stages ( P < 0. 05 ). Enhanced expression of PPARγmRNA was correlated with good prognosis in gastric cancer( P < 0.05 ). Conclusion The expression of PPARγmRNA is significantly correlated with TNM stages. PPARγmRNA may be identified as a novel prognostic indicator and it could be an effective target for gene therapy.